7th Annual Guidelines for Disseminating Off-Label Information

Balance Scientific Discussion with Promotion in an Environment of Increased Regulatory Scrutiny

New Assault on Pharma Marketing?

It's one thing to criticize pharmaceutical marketing techniques like we have seen in the press, in Congress, on this Blog, and elsewhere. But attempting...

Celebrities & Buzz Revisited

Last week's post "Fake Pharma Advertising" elicited a number of responses from members of the PHARMA-MKTING Online Discussion Group. I include the dialog and...

Fake Pharma Advertising

There is a growing concern about using certain promotional techniques for drugs and devices that have been "imported" from other industries (e.g., packaged goods)....

eDetailing: Surveys Say…

At the recent Technology Supported Physician Detailing conference in Philadelphia, Liz Boehm presented data from a recent (2005) Forrester Research survey of eDetailed docs....

DTC & Prescribing: Conventional Wisdom Challenged

With all the hoopla about direct-to-consumer (DTC) advertising and diminishing return on physician detailing, physicians are being surveyed more and more about their attitudes...

Can You Trust eDetailing Surveys?

When using surveys to measure ROI of marketing campaigns -- such as surveys about physician use of eDetailing -- marketers should be wary of comparing one survey's results with another.

Mobile Medical Reference: An Effective Door Opener for Sales Reps

Pharmaceutical companies are searching for new, creative solutions to the problem of decreasing sales rep effectiveness. One such solution is to provide physicians with value-added smart tools to allow them instant access to up-to-date prescribing and treatment information.

Society of Industry Leaders: Help for Investors

The shifting pharma landscape makes it all the more important that investors make intelligent choices where to invest their money. The Society of Industry Leaders provides institutional money managers with timely information about the current state of the pharmaceutical market and how it is likely to progress.

Managing Cross Boundary Issues

Pharmaceutical companies are notorious for their functional and organizational silo structure built around brands. Strategic issues that cross silos -- i.e., cross-boundary issues such as getting marketing and R&D working together, getting a more coordinated global approach to marketing, or getting companies to work better in marketing alliances-are thornier than most because managers don't control all the necessary resources and communication and trust are often weak.